Lung Cancer Trial Results
Meta-Analysis Suggests Cisplatin Superior to Carboplatin for Advanced NSCLC
(Posted: 06/19/2007) - Cisplatin is likely a better option than carboplatin for patients with advanced-stage non-small-cell lung cancer (NSCLC), according to a meta-analysis in the June 6, 2007, Journal of the National Cancer Institute.
Surgery Does Not Improve Survival for Advanced NSCLC Patients
(Posted: 04/17/2007) - Patients with advanced non-small-cell lung cancer who had surgery following induction chemotherapy did not have better overall or progression-free survival than patients who received radiotherapy following chemotherapy, according to the March 21, 2007, Journal of the National Cancer Institute.
Longer Course of Radiation Provides Better Palliation in Advanced NSCLC
(Posted: 01/30/2007) - In patients with advanced non-small cell lung cancer and a poor outlook, a longer, less intense course of radiation treatment improved patients' life expectancy and was cost-effective, according to the Dec. 20, 2006, Journal of the National Cancer Institute.
Erlotinib (Tarceva®) Extends Survival in Advanced Lung Cancer
(Posted: 06/05/2004, Updated: 08/30/2006) - Erlotinib (Tarceva®) prolonged survival in patients with advanced non-small cell lung cancer who had progressed after standard chemotherapy, according to findings reported at the 2004 ASCO meeting in New Orleans.
(Posted: 06/19/2007) - Cisplatin is likely a better option than carboplatin for patients with advanced-stage non-small-cell lung cancer (NSCLC), according to a meta-analysis in the June 6, 2007, Journal of the National Cancer Institute.
Surgery Does Not Improve Survival for Advanced NSCLC Patients
(Posted: 04/17/2007) - Patients with advanced non-small-cell lung cancer who had surgery following induction chemotherapy did not have better overall or progression-free survival than patients who received radiotherapy following chemotherapy, according to the March 21, 2007, Journal of the National Cancer Institute.
Longer Course of Radiation Provides Better Palliation in Advanced NSCLC
(Posted: 01/30/2007) - In patients with advanced non-small cell lung cancer and a poor outlook, a longer, less intense course of radiation treatment improved patients' life expectancy and was cost-effective, according to the Dec. 20, 2006, Journal of the National Cancer Institute.
Erlotinib (Tarceva®) Extends Survival in Advanced Lung Cancer
(Posted: 06/05/2004, Updated: 08/30/2006) - Erlotinib (Tarceva®) prolonged survival in patients with advanced non-small cell lung cancer who had progressed after standard chemotherapy, according to findings reported at the 2004 ASCO meeting in New Orleans.
